Rapid Micro Biosystems, Inc. (NASDAQ: RPID) Stock Competitors & Peer Comparison
See RPID's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for RPID and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RPID | $2.13 | +0.95% | 96.5M | -1.90 | -$1.12 | N/A |
| ABT | $105.70 | +0.09% | 184.2B | 20.30 | $5.21 | +2.34% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $325.70 | -6.42% | 124.9B | 24.32 | $13.39 | +1.07% |
| MDT | $85.39 | -0.37% | 109.3B | 15.44 | $5.53 | +3.32% |
| BSX | $46.73 | +1.59% | 69.4B | 15.07 | $3.10 | N/A |
| EW | $86.07 | -0.98% | 49.5B | 31.87 | $2.70 | N/A |
| DXCM | $83.45 | +11.95% | 32.2B | 35.82 | $2.33 | N/A |
| RMD | $210.98 | +1.16% | 30.6B | 19.59 | $10.77 | +1.14% |
| PHG | $26.30 | -0.53% | 25.7B | 15.03 | $1.75 | +3.78% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
RPID vs ABT Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, ABT has a market cap of 184.2B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while ABT trades at $105.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas ABT's P/E ratio is 20.30. In terms of profitability, RPID's ROE is -1.32%, compared to ABT's ROE of +0.11%. Regarding short-term risk, RPID is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for RPID.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
RPID vs BSX-PA Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, RPID's ROE is -1.32%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, RPID is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for RPID.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
RPID vs SYK Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, SYK has a market cap of 124.9B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while SYK trades at $325.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas SYK's P/E ratio is 24.32. In terms of profitability, RPID's ROE is -1.32%, compared to SYK's ROE of +0.16%. Regarding short-term risk, RPID is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for RPID.Check SYK's competition here
Medtronic plc (NYSE: MDT)
RPID vs MDT Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, MDT has a market cap of 109.3B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while MDT trades at $85.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas MDT's P/E ratio is 15.44. In terms of profitability, RPID's ROE is -1.32%, compared to MDT's ROE of +0.10%. Regarding short-term risk, RPID is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for RPID.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
RPID vs BSX Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, BSX has a market cap of 69.4B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while BSX trades at $46.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas BSX's P/E ratio is 15.07. In terms of profitability, RPID's ROE is -1.32%, compared to BSX's ROE of +0.15%. Regarding short-term risk, RPID is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for RPID.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
RPID vs EW Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, EW has a market cap of 49.5B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while EW trades at $86.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas EW's P/E ratio is 31.87. In terms of profitability, RPID's ROE is -1.32%, compared to EW's ROE of +0.10%. Regarding short-term risk, RPID is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for RPID.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
RPID vs DXCM Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, DXCM has a market cap of 32.2B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while DXCM trades at $83.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas DXCM's P/E ratio is 35.82. In terms of profitability, RPID's ROE is -1.32%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, RPID is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for RPID.Check DXCM's competition here
ResMed Inc. (NYSE: RMD)
RPID vs RMD Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, RMD has a market cap of 30.6B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while RMD trades at $210.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas RMD's P/E ratio is 19.59. In terms of profitability, RPID's ROE is -1.32%, compared to RMD's ROE of +0.24%. Regarding short-term risk, RPID is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for RPID.Check RMD's competition here
Koninklijke Philips N.V. (NYSE: PHG)
RPID vs PHG Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, PHG has a market cap of 25.7B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while PHG trades at $26.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas PHG's P/E ratio is 15.03. In terms of profitability, RPID's ROE is -1.32%, compared to PHG's ROE of +0.10%. Regarding short-term risk, RPID is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for RPID.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
RPID vs ZBH Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, ZBH has a market cap of 18.2B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while ZBH trades at $93.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas ZBH's P/E ratio is 11.08. In terms of profitability, RPID's ROE is -1.32%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, RPID is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for RPID.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
RPID vs ABMD Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas ABMD's P/E ratio is 65.36. In terms of profitability, RPID's ROE is -1.32%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, RPID is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for RPID.Check ABMD's competition here
Smith & Nephew plc (NYSE: SNN)
RPID vs SNN Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, SNN has a market cap of 13.3B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while SNN trades at $31.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas SNN's P/E ratio is 17.02. In terms of profitability, RPID's ROE is -1.32%, compared to SNN's ROE of +0.12%. Regarding short-term risk, RPID is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for RPID.Check SNN's competition here
Penumbra, Inc. (NYSE: PEN)
RPID vs PEN Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while PEN trades at $321.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas PEN's P/E ratio is 83.87. In terms of profitability, RPID's ROE is -1.32%, compared to PEN's ROE of +0.11%. Regarding short-term risk, RPID is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for RPID.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
RPID vs SWAV Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas SWAV's P/E ratio is 78.76. In terms of profitability, RPID's ROE is -1.32%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, RPID is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for RPID.Check SWAV's competition here
Align Technology, Inc. (NASDAQ: ALGN)
RPID vs ALGN Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while ALGN trades at $169.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas ALGN's P/E ratio is 15.81. In terms of profitability, RPID's ROE is -1.32%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, RPID is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for RPID.Check ALGN's competition here
Insulet Corp. (NASDAQ: PODD)
RPID vs PODD Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, PODD has a market cap of 11.5B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while PODD trades at $165.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas PODD's P/E ratio is 30.73. In terms of profitability, RPID's ROE is -1.32%, compared to PODD's ROE of +0.21%. Regarding short-term risk, RPID is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for RPID.Check PODD's competition here
Globus Medical, Inc. (NYSE: GMED)
RPID vs GMED Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, GMED has a market cap of 10.6B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while GMED trades at $78.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas GMED's P/E ratio is 17.75. In terms of profitability, RPID's ROE is -1.32%, compared to GMED's ROE of +0.13%. Regarding short-term risk, RPID is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for RPID.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
RPID vs GKOS Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, GKOS has a market cap of 9.8B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while GKOS trades at $166.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas GKOS's P/E ratio is -194.15. In terms of profitability, RPID's ROE is -1.32%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, RPID is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for RPID.Check GKOS's competition here
Bruker Corporation (NASDAQ: BRKR)
RPID vs BRKR Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, BRKR has a market cap of 9.6B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while BRKR trades at $62.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas BRKR's P/E ratio is 34.53. In terms of profitability, RPID's ROE is -1.32%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, RPID is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for RPID.Check BRKR's competition here
Masimo Corporation (NASDAQ: MASI)
RPID vs MASI Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas MASI's P/E ratio is 44.43. In terms of profitability, RPID's ROE is -1.32%, compared to MASI's ROE of +0.09%. Regarding short-term risk, RPID is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for RPID.Check MASI's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
RPID vs BIO-B Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, BIO-B has a market cap of 9.2B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while BIO-B trades at $320.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas BIO-B's P/E ratio is 95.08. In terms of profitability, RPID's ROE is -1.32%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, RPID is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for RPID.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
RPID vs BIO Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, BIO has a market cap of 8.8B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while BIO trades at $325.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas BIO's P/E ratio is 35.12. In terms of profitability, RPID's ROE is -1.32%, compared to BIO's ROE of +0.02%. Regarding short-term risk, RPID is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for RPID.Check BIO's competition here
Inari Medical, Inc. (NASDAQ: NARI)
RPID vs NARI Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas NARI's P/E ratio is -59.24. In terms of profitability, RPID's ROE is -1.32%, compared to NARI's ROE of -0.00%. Regarding short-term risk, RPID is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for RPID.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
RPID vs LIVN Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, LIVN has a market cap of 4.4B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while LIVN trades at $80.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas LIVN's P/E ratio is 20.04. In terms of profitability, RPID's ROE is -1.32%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, RPID is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for RPID.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
RPID vs ITGR Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, ITGR has a market cap of 4.1B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while ITGR trades at $121.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas ITGR's P/E ratio is 19.24. In terms of profitability, RPID's ROE is -1.32%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, RPID is less volatile compared to ITGR. This indicates lower risk in terms of short-term price fluctuations for RPID.Check ITGR's competition here
Haemonetics Corporation (NYSE: HAE)
RPID vs HAE Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, HAE has a market cap of 3.9B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while HAE trades at $85.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas HAE's P/E ratio is 17.22. In terms of profitability, RPID's ROE is -1.32%, compared to HAE's ROE of +0.11%. Regarding short-term risk, RPID is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for RPID.Check HAE's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
RPID vs IRTC Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, IRTC has a market cap of 3.9B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while IRTC trades at $117.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas IRTC's P/E ratio is -209.23. In terms of profitability, RPID's ROE is -1.32%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, RPID is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for RPID.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
RPID vs AXNX Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas AXNX's P/E ratio is -709.80. In terms of profitability, RPID's ROE is -1.32%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, RPID is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for RPID.Check AXNX's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
RPID vs ESTA Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, ESTA has a market cap of 2.7B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while ESTA trades at $92.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas ESTA's P/E ratio is -64.26. In terms of profitability, RPID's ROE is -1.32%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, RPID is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for RPID.Check ESTA's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
RPID vs TMDX Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, TMDX has a market cap of 2.6B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while TMDX trades at $76.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas TMDX's P/E ratio is 31.23. In terms of profitability, RPID's ROE is -1.32%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, RPID is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for RPID.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
RPID vs AXGN Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, AXGN has a market cap of 2.2B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while AXGN trades at $42.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas AXGN's P/E ratio is 111.08. In terms of profitability, RPID's ROE is -1.32%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, RPID is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for RPID.Check AXGN's competition here
NuVasive, Inc. (NASDAQ: NUVA)
RPID vs NUVA Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas NUVA's P/E ratio is 75.00. In terms of profitability, RPID's ROE is -1.32%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, RPID is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for RPID.Check NUVA's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
RPID vs UFPT Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, UFPT has a market cap of 2B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while UFPT trades at $254.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas UFPT's P/E ratio is 26.54. In terms of profitability, RPID's ROE is -1.32%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, RPID is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for RPID.Check UFPT's competition here
Butterfly Network, Inc. (NYSE: BFLY)
RPID vs BFLY Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, BFLY has a market cap of 1.9B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while BFLY trades at $7.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas BFLY's P/E ratio is -29.60. In terms of profitability, RPID's ROE is -1.32%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, RPID is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for RPID.Check BFLY's competition here
Novocure Ltd (NASDAQ: NVCR)
RPID vs NVCR Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, NVCR has a market cap of 1.7B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while NVCR trades at $14.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas NVCR's P/E ratio is -9.70. In terms of profitability, RPID's ROE is -1.32%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, RPID is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for RPID.Check NVCR's competition here
Enovis Corporation (NYSE: ENOV)
RPID vs ENOV Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, ENOV has a market cap of 1.7B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while ENOV trades at $29.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas ENOV's P/E ratio is 8.63. In terms of profitability, RPID's ROE is -1.32%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, RPID is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for RPID.Check ENOV's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
RPID vs ATEC Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while ATEC trades at $9.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas ATEC's P/E ratio is -86.55. In terms of profitability, RPID's ROE is -1.32%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, RPID is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for RPID.Check ATEC's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
RPID vs AHCO Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, AHCO has a market cap of 1.5B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while AHCO trades at $10.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas AHCO's P/E ratio is 24.27. In terms of profitability, RPID's ROE is -1.32%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, RPID is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for RPID.Check AHCO's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
RPID vs INSP Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, INSP has a market cap of 1.4B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while INSP trades at $50.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas INSP's P/E ratio is 19.43. In terms of profitability, RPID's ROE is -1.32%, compared to INSP's ROE of +0.18%. Regarding short-term risk, RPID is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for RPID.Check INSP's competition here
CONMED Corporation (NYSE: CNMD)
RPID vs CNMD Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while CNMD trades at $46.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas CNMD's P/E ratio is 10.21. In terms of profitability, RPID's ROE is -1.32%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, RPID is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for RPID.Check CNMD's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
RPID vs TNDM Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while TNDM trades at $19.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas TNDM's P/E ratio is -17.73. In terms of profitability, RPID's ROE is -1.32%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, RPID is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for RPID.Check TNDM's competition here
Heska Corporation (NASDAQ: HSKA)
RPID vs HSKA Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas HSKA's P/E ratio is -62.49. In terms of profitability, RPID's ROE is -1.32%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, RPID is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for RPID.Check HSKA's competition here
Artivion, Inc. (NYSE: AORT)
RPID vs AORT Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while AORT trades at $26.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas AORT's P/E ratio is 41.26. In terms of profitability, RPID's ROE is -1.32%, compared to AORT's ROE of +0.03%. Regarding short-term risk, RPID is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for RPID.Check AORT's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
RPID vs IART Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while IART trades at $16.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas IART's P/E ratio is 7.06. In terms of profitability, RPID's ROE is -1.32%, compared to IART's ROE of -0.01%. Regarding short-term risk, RPID is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for RPID.Check IART's competition here
Avanos Medical, Inc. (NYSE: AVNS)
RPID vs AVNS Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas AVNS's P/E ratio is 27.77. In terms of profitability, RPID's ROE is -1.32%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, RPID is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for RPID.Check AVNS's competition here
IRadimed Corporation (NASDAQ: IRMD)
RPID vs IRMD Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while IRMD trades at $90.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas IRMD's P/E ratio is 45.66. In terms of profitability, RPID's ROE is -1.32%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, RPID is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for RPID.Check IRMD's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
RPID vs SILK Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas SILK's P/E ratio is -18.96. In terms of profitability, RPID's ROE is -1.32%, compared to SILK's ROE of -0.35%. Regarding short-term risk, RPID is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for RPID.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
RPID vs FNA Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas FNA's P/E ratio is -19.83. In terms of profitability, RPID's ROE is -1.32%, compared to FNA's ROE of -0.35%. Regarding short-term risk, RPID is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for RPID.Check FNA's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
RPID vs PRCT Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, PRCT has a market cap of 1.1B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while PRCT trades at $18.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas PRCT's P/E ratio is -10.23. In terms of profitability, RPID's ROE is -1.32%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, RPID is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for RPID.Check PRCT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
RPID vs LMRI Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, LMRI has a market cap of 1B. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while LMRI trades at $10.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas LMRI's P/E ratio is -20.25. In terms of profitability, RPID's ROE is -1.32%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, RPID is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for RPID.Check LMRI's competition here
Bioventus Inc. (NASDAQ: BVS)
RPID vs BVS Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, BVS has a market cap of 892.2M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while BVS trades at $13.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas BVS's P/E ratio is 17.56. In terms of profitability, RPID's ROE is -1.32%, compared to BVS's ROE of +0.16%. Regarding short-term risk, RPID is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for RPID.Check BVS's competition here
InMode Ltd. (NASDAQ: INMD)
RPID vs INMD Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, INMD has a market cap of 870.3M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while INMD trades at $15.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas INMD's P/E ratio is 9.71. In terms of profitability, RPID's ROE is -1.32%, compared to INMD's ROE of +0.13%. Regarding short-term risk, RPID is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for RPID.Check INMD's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
RPID vs CSII Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas CSII's P/E ratio is -20.83. In terms of profitability, RPID's ROE is -1.32%, compared to CSII's ROE of -0.14%. Regarding short-term risk, RPID is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for RPID.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
RPID vs SIBN Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, SIBN has a market cap of 787.6M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while SIBN trades at $17.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas SIBN's P/E ratio is -45.54. In terms of profitability, RPID's ROE is -1.32%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, RPID is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for RPID.Check SIBN's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
RPID vs SSII Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, SSII has a market cap of 784.5M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while SSII trades at $3.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas SSII's P/E ratio is -76.46. In terms of profitability, RPID's ROE is -1.32%, compared to SSII's ROE of -0.23%. Regarding short-term risk, RPID is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for RPID.Check SSII's competition here
CeriBell, Inc. (NASDAQ: CBLL)
RPID vs CBLL Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, CBLL has a market cap of 671.2M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while CBLL trades at $17.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas CBLL's P/E ratio is -10.85. In terms of profitability, RPID's ROE is -1.32%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, RPID is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for RPID.Check CBLL's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
RPID vs TCMD Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, TCMD has a market cap of 635.4M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while TCMD trades at $28.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas TCMD's P/E ratio is 32.01. In terms of profitability, RPID's ROE is -1.32%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, RPID is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for RPID.Check TCMD's competition here
Surmodics, Inc. (NASDAQ: SRDX)
RPID vs SRDX Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas SRDX's P/E ratio is -34.66. In terms of profitability, RPID's ROE is -1.32%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, RPID is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for RPID.Check SRDX's competition here
BrainsWay Ltd. (NASDAQ: BWAY)
RPID vs BWAY Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, BWAY has a market cap of 597.4M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while BWAY trades at $15.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas BWAY's P/E ratio is 38.69. In terms of profitability, RPID's ROE is -1.32%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, RPID is less volatile compared to BWAY. This indicates lower risk in terms of short-term price fluctuations for RPID.Check BWAY's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
RPID vs APEN Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas APEN's P/E ratio is -9.43. In terms of profitability, RPID's ROE is -1.32%, compared to APEN's ROE of -0.85%. Regarding short-term risk, RPID is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for RPID.Check APEN's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
RPID vs BBNX Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, BBNX has a market cap of 577.2M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while BBNX trades at $12.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas BBNX's P/E ratio is -8.50. In terms of profitability, RPID's ROE is -1.32%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, RPID is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for RPID.Check BBNX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
RPID vs CTKB Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, CTKB has a market cap of 545M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while CTKB trades at $4.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas CTKB's P/E ratio is -32.46. In terms of profitability, RPID's ROE is -1.32%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, RPID is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for RPID.Check CTKB's competition here
ZimVie Inc. (NASDAQ: ZIMV)
RPID vs ZIMV Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, RPID's ROE is -1.32%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, RPID is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for RPID.Check ZIMV's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
RPID vs KIDS Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, KIDS has a market cap of 518.6M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while KIDS trades at $20.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas KIDS's P/E ratio is -19.60. In terms of profitability, RPID's ROE is -1.32%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, RPID is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for RPID.Check KIDS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
RPID vs OFIX Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, OFIX has a market cap of 477M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while OFIX trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas OFIX's P/E ratio is -48.07. In terms of profitability, RPID's ROE is -1.32%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, RPID is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for RPID.Check OFIX's competition here
Varex Imaging Corporation (NASDAQ: VREX)
RPID vs VREX Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, VREX has a market cap of 471.1M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while VREX trades at $11.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas VREX's P/E ratio is 11.78. In terms of profitability, RPID's ROE is -1.32%, compared to VREX's ROE of -0.18%. Regarding short-term risk, RPID is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for RPID.Check VREX's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
RPID vs CLPT Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, CLPT has a market cap of 448M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while CLPT trades at $14.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas CLPT's P/E ratio is -14.79. In terms of profitability, RPID's ROE is -1.32%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, RPID is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for RPID.Check CLPT's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
RPID vs NPCE Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, NPCE has a market cap of 439.5M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while NPCE trades at $12.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas NPCE's P/E ratio is -22.22. In terms of profitability, RPID's ROE is -1.32%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, RPID is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for RPID.Check NPCE's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
RPID vs PACB Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, PACB has a market cap of 434.8M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while PACB trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas PACB's P/E ratio is -2.86. In terms of profitability, RPID's ROE is -1.32%, compared to PACB's ROE of -4.88%. Regarding short-term risk, RPID is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for RPID.Check PACB's competition here
Cerus Corporation (NASDAQ: CERS)
RPID vs CERS Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, CERS has a market cap of 430.8M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while CERS trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas CERS's P/E ratio is -42.91. In terms of profitability, RPID's ROE is -1.32%, compared to CERS's ROE of -0.10%. Regarding short-term risk, RPID is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for RPID.Check CERS's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
RPID vs DCTH Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, DCTH has a market cap of 421.9M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while DCTH trades at $12.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas DCTH's P/E ratio is 1222.00. In terms of profitability, RPID's ROE is -1.32%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, RPID is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for RPID.Check DCTH's competition here
Carlsmed, Inc. (NASDAQ: CARL)
RPID vs CARL Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, CARL has a market cap of 342.3M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while CARL trades at $12.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas CARL's P/E ratio is -5.02. In terms of profitability, RPID's ROE is -1.32%, compared to CARL's ROE of -0.62%. Regarding short-term risk, RPID is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for RPID.Check CARL's competition here
Electromed, Inc. (AMEX: ELMD)
RPID vs ELMD Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, ELMD has a market cap of 336.3M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while ELMD trades at $40.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas ELMD's P/E ratio is 34.72. In terms of profitability, RPID's ROE is -1.32%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, RPID is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for RPID.Check ELMD's competition here
CapsoVision, Inc. (NASDAQ: CV)
RPID vs CV Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, CV has a market cap of 328.8M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while CV trades at $6.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas CV's P/E ratio is -2.63. In terms of profitability, RPID's ROE is -1.32%, compared to CV's ROE of +1.27%. Regarding short-term risk, RPID is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for RPID.Check CV's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
RPID vs SMLR Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas SMLR's P/E ratio is 3.92. In terms of profitability, RPID's ROE is -1.32%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, RPID is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for RPID.Check SMLR's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
RPID vs AVR Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, AVR has a market cap of 288.4M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while AVR trades at $7.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas AVR's P/E ratio is -3.52. In terms of profitability, RPID's ROE is -1.32%, compared to AVR's ROE of -1.24%. Regarding short-term risk, RPID is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for RPID.Check AVR's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
RPID vs SGHT Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, SGHT has a market cap of 286.2M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while SGHT trades at $5.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas SGHT's P/E ratio is -7.41. In terms of profitability, RPID's ROE is -1.32%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, RPID is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for RPID.Check SGHT's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
RPID vs TMCI Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, TMCI has a market cap of 279.6M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while TMCI trades at $4.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas TMCI's P/E ratio is -4.59. In terms of profitability, RPID's ROE is -1.32%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, RPID is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for RPID.Check TMCI's competition here
Profound Medical Corp. (NASDAQ: PROF)
RPID vs PROF Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, PROF has a market cap of 268.2M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while PROF trades at $7.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas PROF's P/E ratio is -5.95. In terms of profitability, RPID's ROE is -1.32%, compared to PROF's ROE of -0.70%. Regarding short-term risk, RPID is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for RPID.Check PROF's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
RPID vs ANIK Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, ANIK has a market cap of 256.5M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while ANIK trades at $19.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas ANIK's P/E ratio is 39.35. In terms of profitability, RPID's ROE is -1.32%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, RPID is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for RPID.Check ANIK's competition here
RxSight, Inc. (NASDAQ: RXST)
RPID vs RXST Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, RXST has a market cap of 248.8M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while RXST trades at $6.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas RXST's P/E ratio is -8.35. In terms of profitability, RPID's ROE is -1.32%, compared to RXST's ROE of -0.17%. Regarding short-term risk, RPID is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for RPID.Check RXST's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
RPID vs MGRM Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas MGRM's P/E ratio is -12.00. In terms of profitability, RPID's ROE is -1.32%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, RPID is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for RPID.Check MGRM's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
RPID vs FOCL Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, FOCL has a market cap of 229.4M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while FOCL trades at $6.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas FOCL's P/E ratio is -7.87. In terms of profitability, RPID's ROE is -1.32%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, RPID is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for RPID.Check FOCL's competition here
Nevro Corp. (NYSE: NVRO)
RPID vs NVRO Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas NVRO's P/E ratio is -1.91. In terms of profitability, RPID's ROE is -1.32%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, RPID is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for RPID.Check NVRO's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
RPID vs CATX Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, CATX has a market cap of 223.6M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while CATX trades at $2.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas CATX's P/E ratio is -2.05. In terms of profitability, RPID's ROE is -1.32%, compared to CATX's ROE of -0.42%. Regarding short-term risk, RPID is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for RPID.Check CATX's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
RPID vs SENS Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, SENS has a market cap of 210.2M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while SENS trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas SENS's P/E ratio is -2.51. In terms of profitability, RPID's ROE is -1.32%, compared to SENS's ROE of -1.30%. Regarding short-term risk, RPID is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for RPID.Check SENS's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
RPID vs BSGM Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas BSGM's P/E ratio is -5.81. In terms of profitability, RPID's ROE is -1.32%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, RPID is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for RPID.Check BSGM's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
RPID vs MDGS Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas MDGS's P/E ratio is -0.27. In terms of profitability, RPID's ROE is -1.32%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, RPID is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for RPID.Check MDGS's competition here
Inogen, Inc. (NASDAQ: INGN)
RPID vs INGN Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, INGN has a market cap of 174.6M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while INGN trades at $6.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas INGN's P/E ratio is -7.09. In terms of profitability, RPID's ROE is -1.32%, compared to INGN's ROE of -0.13%. Regarding short-term risk, RPID is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for RPID.Check INGN's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
RPID vs TLSI Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, TLSI has a market cap of 172.1M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while TLSI trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas TLSI's P/E ratio is -2.70. In terms of profitability, RPID's ROE is -1.32%, compared to TLSI's ROE of +1.63%. Regarding short-term risk, RPID is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for RPID.Check TLSI's competition here
Quanterix Corporation (NASDAQ: QTRX)
RPID vs QTRX Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, QTRX has a market cap of 163.9M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while QTRX trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas QTRX's P/E ratio is -2.17. In terms of profitability, RPID's ROE is -1.32%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, RPID is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for RPID.Check QTRX's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
RPID vs QIPT Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas QIPT's P/E ratio is -15.87. In terms of profitability, RPID's ROE is -1.32%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, RPID is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for RPID.Check QIPT's competition here
Neuronetics, Inc. (NASDAQ: STIM)
RPID vs STIM Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, STIM has a market cap of 137.8M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while STIM trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas STIM's P/E ratio is -3.67. In terms of profitability, RPID's ROE is -1.32%, compared to STIM's ROE of -1.65%. Regarding short-term risk, RPID is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for RPID.Check STIM's competition here
CVRx, Inc. (NASDAQ: CVRX)
RPID vs CVRX Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, CVRX has a market cap of 137.3M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while CVRX trades at $5.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas CVRX's P/E ratio is -2.56. In terms of profitability, RPID's ROE is -1.32%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, RPID is less volatile compared to CVRX. This indicates lower risk in terms of short-term price fluctuations for RPID.Check CVRX's competition here
Picard Medical, Inc. (AMEX: PMI)
RPID vs PMI Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, PMI has a market cap of 137.1M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while PMI trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas PMI's P/E ratio is -0.07. In terms of profitability, RPID's ROE is -1.32%, compared to PMI's ROE of +4.99%. Regarding short-term risk, RPID is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for RPID.Check PMI's competition here
Avita Medical Inc. (NASDAQ: RCEL)
RPID vs RCEL Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, RCEL has a market cap of 109.3M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while RCEL trades at $4.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas RCEL's P/E ratio is -2.80. In terms of profitability, RPID's ROE is -1.32%, compared to RCEL's ROE of +3.05%. Regarding short-term risk, RPID is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for RPID.Check RCEL's competition here
iCAD, Inc. (NASDAQ: ICAD)
RPID vs ICAD Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas ICAD's P/E ratio is -20.37. In terms of profitability, RPID's ROE is -1.32%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, RPID is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for RPID.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
RPID vs HJLI Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas HJLI's P/E ratio is N/A. In terms of profitability, RPID's ROE is -1.32%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, RPID is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for RPID.Check HJLI's competition here
Solana Company (NASDAQ: HSDT)
RPID vs HSDT Comparison August 2026
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 96.5M. In comparison, HSDT has a market cap of 96.3M. Regarding current trading prices, RPID is priced at $2.13 on the NASDAQ, while HSDT trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -1.90, whereas HSDT's P/E ratio is -0.02. In terms of profitability, RPID's ROE is -1.32%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, RPID is less volatile compared to HSDT. This indicates lower risk in terms of short-term price fluctuations for RPID.Check HSDT's competition here